Intermountain Precision Genomics to Develop Hereditary Cancer Gene Panels
The emerging healthcare model which is dominated by a small number of very large health systems will be characterized, in part, by in-house, sophisticated genomic and molecular lab testing by these systems. This is because these large health systems will have the capital to invest in their own"laboratories of excellence" within their system. Such is the case withIntermountain Healthcare which has its own in-house genomics laboratory called Intermountain Precision Genomics. Intermountain Health is one of the giant health systems with 37,000 employees, 22 hospitals, and more than 185 clinics. Here is the mission statement for this laboratory copied from its web site:At Intermountain Precision Genomics in-house laboratory, experts analyze the DNA and genetic makeup of a cancer patient's tumor, enabling detection of the individual genes with errors in a person's cancer to determine treatment options. The testing is proprietary to Intermountain Healthcare, but access to it is available to oncologists anywhere. The testing serves patients with late-stage cancer who have failed in a traditional treatment method.Intermountain Precision Genomics has just announced a plan to develophereditary cancer gene panels (see: Intermountain Precision Genomics to develop hereditary cancer gene panels). Below is an excerpt from the article describing this new test offering:Intermountain Precision Genomics announced...it will develop hereditary cancer gene panels. I...
This debate pack outlines progress so far in implementing the cancer strategy and provides statistics on survival rates and the NHS cancer workforce. It also collates commentary and analysis from official, parliamentary and third sector organisations.
ABSTRACT Deciphering the complex milieu that makes up the tumor microenvironment (TME) and the signaling engaged by TME cytokines continues to provide novel targets for therapeutic intervention. The IL‐6 family member Oncostatin M (OSM) has recently emerged as a potent driver of tumorigenesis, metastasis and therapy failure, molecular programs most frequently attributed to IL‐6 itself. In a recent issue of The Journal of Pathology, Kucia‐Tran et al. describe how elevated Oncostatin M receptor (OSMR) expression results in a feed‐forward loop involving the de novo production of both OSM and OSMR to facilitate aggress...
This NIHR Signal finds that for western high-income countries such as the UK, an estimated 15% to 16% of cancers could be avoided by preventing diabetes, obesity or excess weight. Although the links between high BMI, diabetes and cancer have been known for some time, this study presents the first calculations of attributable risk for 175 countries. This represents the proportion of cancers that could be prevented if the risk factors were eliminated.
According to this study: Current or recent users of hormonal contraceptives are at higher risk for breast cancer than women who have never used hormonal contraceptives.The risk increases with the duration of use.
Oncology Nurses' Knowledge, Confidence, and Practice in Addressing Caregiver Strain and Burden . Oncol Nurs Forum. 2018 Mar 01;45(2):187-196 Authors: Irwin MM, Dudley W, Northouse L, Berry DL, Mallory GA Abstract OBJECTIVES: To describe nurses' practices, confidence, and knowledge of evidence-based interventions for cancer caregiver strain and burden and to identify factors that contribute to these aspects. . SAMPLE & SETTING: 2,055 Oncology Nursing Society members completed an emailed survey. . METHODS & VARIABLES: Pooled analysis of survey results. Variables included the bas...
In this issue of Parkinsonism and Related Disorders, two studies address the role of biomarkers for atypical parkinsonian syndromes. Interest in testing experimental treatments for disorders like Multiple Systems Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) has increased recently [1,2], both to meet the needs of patients with these disorders and because they can be thought of as model systems for more common conditions, like Alzheimer's disease. Understanding how to use biomarkers for atypical parkinsonian syndromes is a crucial step in this process.
Conclusion: VOL, VBM, and their combination are effective in differential diagnostics between bvFTD and AD or SMC. However, MRI atrophy profiles for bvFTD and LBD are too similar for a reliable differentiation with the quantification methods tested in this study.Dement Geriatr Cogn Disord Extra 2018;8:51 –59
ConclusionIt is feasible and safe to use this novel, flexible, single‐arm robot in performing a transoral robotic radical tonsillectomy and retropharyngeal lymph node dissection.
CONCLUSIONS: The combination of TBx and SBx achieved the best results for the detection and prognosis of PCa-s. The use of SBx alone would have missed the detection of PCa-s in 12% of patients. PMID: 29463177 [PubMed - as supplied by publisher]
CONCLUSIONS: Low-dose brachytherapy offers good short- to intermediate-term cancer control in selected men with localized PCa. Further studies are needed for safety analyses and for comparison with other treatment modalities. PMID: 29463165 [PubMed - as supplied by publisher]